Anita Rajasekhar, MD
Hematology · Gainesville, FLNPI 1437247822
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,198 of the $1,788 with a category attached, or 67.0%. Biomarin Pharmaceutical Inc. accounts for 89.3% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $1,597 and has fallen 96.2% since, to $60 in 2025. That places this record below the midpoint for hematology clinicians in FL, where the typical reported total is $1,704.
Across 9 payments — averaging $198.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biomarin Pharmaceutical Inc.$2K
- Genentech USA, Inc.$77
- CSL Behring$60
- Genentech, Inc.$53
Across 60 payments — averaging $5175.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$115K
- Takeda Pharmaceuticals U.S.A., Inc.$76K
- Bioverativ Therapeutics Inc.$36K
- Biomarin Pharmaceutical Inc.$33K
- Genentech, Inc.$27K
- Ultragenyx Pharmaceutical Inc.$15K
- plus $8K from 1 others
What the payments were for
- Travel & lodging$1,19867%
- Food & beverage$47627%
- Education$1146%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biomarin Pharmaceutical Inc. | 6 | $1,597 |
| Genentech USA, Inc. | 1 | $77 |
| CSL Behring | 1 | $60 |
| Genentech, Inc. | 1 | $53 |
How this compares
$1,788 in reported general payments places this provider in the 50th percentile of 79 hematology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 19 | $16,738 |
| OxycontinOxycodone Hcl | 12 | $9,530 |
| Morphine Sulfate ErMorphine Sulfate | 70 | $2,442 |
| Oxycodone Hcl | 62 | $1,173 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 19 | $453 |
Paid to pharmacies, not to this prescriber.
Other hematology in Gainesville
- Craig KitchensGainesville$11K
- Jack HsuGainesville$3K
- Ansh MehtaGainesville$450
- Zeina Al-MansourGainesville$234
- Peng LiGainesville$164
- Javier Pinilla-IbarzTampa$1.6M
- Rami KomrokjiTampa$855K
- Ahmed ZakariAltamonte Springs$383K
- Alex Mejia GarciaVero Beach$302K
- Doris HansenTampa$141K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.